PT  - JOURNAL ARTICLE
AU  - Sun, Zeguo
AU  - Zhang, Zhongyang
AU  - Banu, Khadija
AU  - Azzi, Yorg Al
AU  - Reghuvaran, Anand
AU  - Fredericks, Samuel
AU  - Planoutene, Marina
AU  - Hartzell, Susan
AU  - Pell, John
AU  - Tietjen, Gregory
AU  - Asch, William
AU  - Kulkarni, Sanjay
AU  - Formica, Richard
AU  - Rana, Meenakshi
AU  - Zhang, Weijia
AU  - Akalin, Enver
AU  - Cravedi, Paolo
AU  - Heeger, Peter S.
AU  - Menon, Madhav C.
TI  - Blood transcriptomes of SARS-CoV-2 infected kidney transplant recipients demonstrate immune insufficiency
AID  - 10.1101/2022.01.31.22270203
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.31.22270203
4099  - http://medrxiv.org/content/early/2022/02/01/2022.01.31.22270203.short
4100  - http://medrxiv.org/content/early/2022/02/01/2022.01.31.22270203.full
AB  - Background Kidney transplant recipients (KTRs) with COVID-19 have poor outcomes compared to non-KTRs. To provide insight into management of immunosuppression during acute illness, we studied immune signatures from the peripheral blood during and after COVID-19 infection from a multicenter KTR cohort.□Methods Clinical data were collected by chart review. PAXgene blood RNA was poly-A selected and RNA sequencing was performed to evaluate transcriptome changes.Results A total of 64 cases of COVID-19 in KTRs were enrolled, including 31 acute cases (< 4 weeks from diagnosis) and 33 post-acute cases (>4 weeks). In the blood transcriptome of acute cases, we identified differentially expressed genes (DEGs) in positive or negative association COVID-19 severity scores. Functional enrichment analyses showed upregulation of neutrophil and innate immune pathways, but downregulation of T-cell and adaptive immune-activation pathways proportional to severity score. This finding was independent of lymphocyte count and despite reduction in immunosuppression (IS) in most KTRs. Comparison with post-acute cases showed “normalization” of these enriched pathways after >4 weeks, suggesting recovery of adaptive immune system activation despite reinstitution of IS. The latter analysis was adjusted for COVID-19 severity score and lymphocyte count. DEGs associated with worsening disease severity in a non-KTR cohort with COVID-19 (GSE152418) showed significant overlap with KTRs in these identified enriched pathways.Conclusion Blood transcriptome of KTRs affected by COVID-19 shows decrease in T-cell and adaptive immune activation pathways during acute disease that associate with severity despite IS reduction and show recovery after acute illness.Significance statement Kidney transplant recipients (KTRs) are reported to have worse outcomes with COVID-19, and empiric reduction of maintenance immunosuppression is pursued. Surprisingly, reported rates of acute rejection have been low despite reduced immunosuppression. We evaluated the peripheral blood transcriptome of 64 KTRs either during or after acute COVID-19. We identified transcriptomic signatures consistent with suppression of adaptive T-cell responses which significantly associated with disease severity and showed evidence of recovery after acute disease, even after adjustment for lymphocyte number. Our transcriptomic findings of immune-insufficiency during acute COVID-19 provide an explanation for the low rates of acute rejection in KTRs despite reduced immunosuppression. Our data support the approach of temporarily reducing T –cell-directed immunosuppression in KTRs with acute COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAuthors acknowledge support from NIH NIAID via ancillary mechanistic grant associated with Grant 3U01AI063594‐17S1 awarded to MCM and PC. (Parent award 3U01AI063594 to PSH). MCM also acknowledges research support from NIH RO1DK122164. We acknowledge Ricarda Tomlin at Yale, Brandy Haydel at Mount Sinai and our cohort of patients for participation in this study during the pandemic.This work was supported in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Independent institutional review board (IRB) approvals from Icahn school of medicine at Mount Sinai (IRB 20-03454) and Montefiore Medical Center (IRB 2020-11662) were obtained for prospective sample and data collection before initiation of the study protocol. Informed consent was obtained from participants and/or representative proxies per these protocols.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at GSE195796 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE195796